Frank Hennemann sometimes coughs 400 times a day. His airways are damaged by a lung condition called bronchiectasis, which he describes as feeling like two trucks are parking on his chest.
After decades of research, there’s finally a medicine to alleviate his symptoms, but Hennemann lives in Germany. One reason he can’t get it there is Donald Trump.
The company behind the new treatment, Insmed Inc., won’t launch in Europe until it can better understand the financial implications of a Trump directive that could upend the math drugmakers rely on to recoup their research investments.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.